 | This article contains promotional content. Please help improve it by removing promotional language and inappropriate external links, and by adding encyclopedic text written from a neutral point of view. (July 2021) (Learn how and when to remove this message) |
 | |
| Company type | Private |
|---|---|
| Industry | |
| Founded | 2011; 13 years ago (2011) |
| Founders |
|
| Headquarters | Berlin, Germany |
| Products | mHealth, Clinical decision support system, Artificial intelligence in healthcare |
| Services | Enterprise software, Telemedicine, medical research |
| Number of employees | 300 (2023) |
| Website | ada |
Ada Health was founded in 2011, by Dr. Claire Novorol, Professor Martin Hirsch, and Daniel Nathrath.
Ada Health is a provider of artificial intelligence (AI) and machine learning tools. The company has headquarters in Berlin, with offices in Boca Raton, London, and Toronto.
History
Ada was established in 2011 by Dr. Claire Novorol (a clinician), Professor Martin Hirsch (an expert in artificial intelligence) and Daniel Nathrath (an entrepreneur). Dr. Novorol, a provider in the UK's National Health Service, found inspiration for the company in clinical genetics, after successfully diagnosing a baby with a rare genetic condition through her searches in medical literature and scientific databases at Addenbrooke's Hospital, Cambridge. Upon recognizing the potential for digital tools to aid in faster and more accurate decision-making for doctors, she founded a digital health network for medical professionals called "Doctorpreneurs". It was through this network that she met her co-founders in Berlin. Ada's first product, "Ada DX" was originally a clinical decision support technology aimed at assisting doctors in accurately diagnosing rare diseases. The system used a Bayesian probabilistic reasoning system based on the medical history and differential diagnosis approaches used in clinical medicine. A doctor would input the patient's signs, symptoms, and findings, and the system would provide a ranked list of probabilistic conditions. A visual display would also indicate how each data point entered had contributed to the relative statistical weighting of the probable conditions suggested.
Medical Focus
In 2016, the business pivoted from supporting doctors directly to supporting patients experiencing a new health problem with a browser-based online tool and smartphone app, commonly referred to as a "symptom checker" called Assess. Users enter their demographics, medical history, and interact with a chatbot that asks them about the symptoms, duration of illness, and severity of the problems they are experiencing. The Assess tool is available for a wide variety of patients, including children, pregnant people, those with mental health concerns, and the elderly. The probabilistic reasoning software supporting the software dynamically adjusts the questions asked to the user based on their previous answer, while also trying to ask as few questions as possible to prevent fatigue. This reasoning software is supported by a medical knowledge base built and reviewed by doctors that references the scientific medical literature, textbooks, regional epidemiology, disease models, and case reports including a range of several thousand common and rare diseases. At the end of their assessment the user is presented with a "triage" recommendation that suggests the level of urgency required and directs users to care options ranging from self-care at home to immediately seeking emergency care. In addition the app lists a number of "possible causes" that suggest medical conditions that might be causing the problem. Ada's software is available in English (US and UK), German, Spanish, Portuguese, Swahili, Romanian, and French.
Regulatory Classification
Ada's product available to healthcare enterprise clients, and the Ada consumer app (i.e. downloadable from app stores) are both CE-certified Class IIa medical devices under the European Union's Medical Device Regulation (Regulation (EU) 2017/745, EU-MRR). The company operates a quality management system certified under ISO 13485, and in the UK has passed UKCA marking assessment.
Media coverage
Ada has been compared to WebMD, Babylon's GP at Hand app, and Your.MD. In October 2017, when three apps were tested with symptoms from asthma, shingles, alcohol-related liver disease, and urinary tract infection, Ada performed very well; it asked about the most important symptoms and provided the best diagnoses. It produced diagrams showing which of the symptoms for each disease were present, the strength of the link, and a diagram of the percentage of people likely to have that diagnosis.
In September 2020, Broadband Commission for Sustainable Development issued a report identifying Ada as one of the AI solutions that have the "potential to address existing health inequalities and provide medical expertise to clinicians, health workers, and patients alike – all with the aim of improving the quality, access, and cost of healthcare delivery."
Rare diseases
A 2019, retrospective study evaluated Ada DX in rare disease diagnosis. Ada's top suggestion matched the confirmed diagnosis in 89% of cases (83 of 93 cases). In more than 56% of cases, Ada provided correct disease suggestions earlier than the time of clinical diagnosis. More than 33% of patients could have been identified as having a rare disease in the first documented clinical visit.
References
- ^ "Ada Health says, "call it" to the Series B round, now at $120 million". Tech.eu. 2022-02-10. Retrieved 2023-12-22.
- Allen, Patricia (2022-02-10). "Berlin-based healthtech startup Ada Health closes Series B at over €105 million to accelerate growth". EU-Startups. Retrieved 2023-12-22.
- "Imprint". Ada. Retrieved 2024-10-28.
- ^ Heathman, Amelia (2018-12-12). "The women leading the healthcare revolution through tech". Evening Standard. Retrieved 2023-05-25.
- ^ Ronicke, Simon; Hirsch, Martin C.; Türk, Ewelina; Larionov, Katharina; Tientcheu, Daphne; Wagner, Annette D. (2019). "Can a decision support system accelerate rare disease diagnosis? Evaluating the potential impact of Ada DX in a retrospective study". Orphanet Journal of Rare Diseases. 14 (1): 69. doi:10.1186/s13023-019-1040-6. ISSN 1750-1172. PMC 6427854. PMID 30898118.
- Semigran, Hannah L; Linder, Jeffrey A; Gidengil, Courtney; Mehrotra, Ateev (2015-07-08). "Evaluation of symptom checkers for self diagnosis and triage: audit study". BMJ. 351: h3480. doi:10.1136/bmj.h3480. ISSN 1756-1833. PMC 4496786. PMID 26157077.
- ^ Miller, Stephen; Gilbert, Stephen; Virani, Vishaal; Wicks, Paul (2020-07-10). "Patients' Utilization and Perception of an Artificial Intelligence–Based Symptom Assessment and Advice Technology in a British Primary Care Waiting Room: Exploratory Pilot Study". JMIR Human Factors. 7 (3): e19713. doi:10.2196/19713. ISSN 2292-9495. PMC 7382011. PMID 32540836.
- Turner, Ben (2020-05-16). "Tanzania's digital doctor learns to speak Swahili". Financial Times. Retrieved 2023-05-25.
- "Can you really trust the medical apps on your phone?". Wired. 1 October 2017. Retrieved 22 September 2018.
- "Working Group on Digital and AI in Health" (PDF). broadbandcommission.org. September 2020. Retrieved 5 April 2023.
- Ronicke, Simon; Hirsch, Martin C.; Türk, Ewelina; Larionov, Katharina; Tientcheu, Daphne; Wagner, Annette D. (2019). "Can a decision support system accelerate rare disease diagnosis? Evaluating the potential impact of Ada DX in a retrospective study". Orphanet Journal of Rare Diseases. 14 (1): 69. doi:10.1186/s13023-019-1040-6. PMC 6427854. PMID 30898118.